---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005581"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:28:17.440574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aptose Biosciences appoints EY as auditor and receives additional $1.5M from Hanmi for tuspetinib

## Summary
- Shareholders voted 96.95% in favor of appointing Ernst & Young LLP as independent registered public accounting firm.
- Received an additional US$1.5M advance from Hanmi Pharmaceutical under the existing US$8.5M loan facility.
- Total advances under the loan facility now US$7.1M to support clinical development of tuspetinib.
- Funds will be used to continue development of tuspetinib-based triple drug frontline therapy for newly diagnosed AML.

## SEC filing metadata
- accession: 0001171843-25-005581
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325005581/0001171843-25-005581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325005581/f8k_082525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005581
- JSON: https://secwatch.observer/filing/0001171843-25-005581.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005581.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.